185,000 Shares in BridgeBio Pharma, Inc. (NASDAQ:BBIO) Acquired by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. purchased a new position in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 185,000 shares of the company's stock, valued at approximately $5,076,000. Jefferies Financial Group Inc. owned about 0.10% of BridgeBio Pharma at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Steward Partners Investment Advisory LLC raised its holdings in shares of BridgeBio Pharma by 85.8% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 1,022 shares of the company's stock worth $28,000 after purchasing an additional 472 shares during the last quarter. Itau Unibanco Holding S.A. purchased a new position in shares of BridgeBio Pharma during the fourth quarter worth $41,000. Sterling Capital Management LLC raised its holdings in shares of BridgeBio Pharma by 554.6% during the fourth quarter. Sterling Capital Management LLC now owns 1,787 shares of the company's stock worth $49,000 after purchasing an additional 1,514 shares during the last quarter. GF Fund Management CO. LTD. purchased a new position in shares of BridgeBio Pharma during the fourth quarter worth $109,000. Finally, First Bank & Trust purchased a new position in shares of BridgeBio Pharma during the fourth quarter worth $205,000. Hedge funds and other institutional investors own 99.85% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on BBIO shares. Redburn Atlantic began coverage on shares of BridgeBio Pharma in a report on Monday, March 31st. They set a "buy" rating and a $50.00 target price for the company. JPMorgan Chase & Co. raised their price target on shares of BridgeBio Pharma from $44.00 to $50.00 and gave the company an "overweight" rating in a research report on Monday, March 24th. Citigroup raised their price target on shares of BridgeBio Pharma from $45.00 to $49.00 and gave the company a "buy" rating in a research report on Friday, February 21st. UBS Group raised their price target on shares of BridgeBio Pharma from $65.00 to $72.00 and gave the company a "buy" rating in a research report on Wednesday, April 30th. Finally, Piper Sandler raised their price target on shares of BridgeBio Pharma from $46.00 to $63.00 and gave the company an "overweight" rating in a research report on Wednesday, April 30th. One equities research analyst has rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $57.09.

Insider Transactions at BridgeBio Pharma

In other BridgeBio Pharma news, CAO Maricel Apuli sold 1,026 shares of the business's stock in a transaction dated Friday, May 2nd. The shares were sold at an average price of $38.51, for a total value of $39,511.26. Following the transaction, the chief accounting officer now directly owns 147,639 shares in the company, valued at $5,685,577.89. The trade was a 0.69% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Neil Kumar sold 75,000 shares of the business's stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $33.40, for a total transaction of $2,505,000.00. Following the completion of the transaction, the chief executive officer now owns 4,798,447 shares in the company, valued at $160,268,129.80. The trade was a 1.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 12,392,182 shares of company stock valued at $416,921,291. Corporate insiders own 18.20% of the company's stock.

BridgeBio Pharma Stock Down 2.5%

Shares of NASDAQ BBIO traded down $0.84 during trading on Wednesday, hitting $32.26. The company had a trading volume of 2,470,729 shares, compared to its average volume of 2,444,469. The stock has a fifty day simple moving average of $34.42 and a two-hundred day simple moving average of $31.97. BridgeBio Pharma, Inc. has a fifty-two week low of $21.62 and a fifty-two week high of $39.54. The firm has a market capitalization of $6.13 billion, a price-to-earnings ratio of -11.32 and a beta of 1.15.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last announced its earnings results on Tuesday, April 29th. The company reported ($0.88) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.00) by $0.12. The company had revenue of $36.74 million during the quarter, compared to analyst estimates of $57.14 million. The firm's revenue for the quarter was down 44.8% compared to the same quarter last year. During the same quarter last year, the business earned ($0.20) EPS. On average, analysts anticipate that BridgeBio Pharma, Inc. will post -3.67 earnings per share for the current year.

BridgeBio Pharma Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.